{"prompt": "['CANOPY GROWTH', 'Protocol #710-4502', 'CORPORATION', 'The following amendments have been made to the original version of the protocol (dated 7 October,', '2020).', 'Version 1.1 (25 November 2020)', 'On the title page of the protocol we included the legal entity 11318152 Canada Inc. This was a request from the', 'Study Insurance Broker.', 'Appendix 6 Classification of Chronic Pain IASP ICD 11 was developed to further illustrate Subject Inclusion', 'Criteria. The definition of Subject Inclusion Criteria 1. was changed from \"Subject > 25 years of age with a', 'diagnosis of chronic non-cancer pain defined as pain lasting or recurring over a period > 3 months (IASP-ICD-11', 'classification)\" to \"Subject > 25 years of age with a diagnosis of chronic non-cancer pain defined as pain lasting', 'or recurring over a period > 3 months (IASP-ICD-11 classification, refer to Appendix 6)\". Changes were made in', 'several places in the protocol to reflect this change, including in the table of contents (p.5), the Synopsis (p. 10),', 'Section 6.1 (Subject Inclusion Criteria p. 21), and Appendix 6 (p. 79).', 'The ST Discontinuation and Exit Assessment are now two separate assessments. Changes were made in several', 'places in the protocol to reflect this change including in the table of contents (p.5), the Synopsis (p. 9), in Table', '1. (Schedule of Events p. 12), Section 3.1. (Study Design p. 17), in Appendix 4 (ST Discontinuation p. 76) and in', 'Appendix 5 (Exit Assessment p. 78).', '25 November 2020', 'CONFIDENTIAL', 'Page 1 of 79']['CANOPY GROWTH', 'Protocol #710-4502', 'CORPORATION', 'Global Registry for the Use of Spectrum Therapeutics', 'Cannabis Products in Subjects with Chronic Pain', 'Protocol Number:', '[710-4502', 'Investigational Product(s):', 'Spectrum Therapeutics Products all formulations: Red,', 'Blue, Yellow, Clear, Orange, Purple, Green', 'Original Protocol', '7 October, 2020', 'Protocol Amendments', '25 Nov, 2020', 'Development Phase:', 'Observational Study', 'Therapeutic Area:', 'Chronic pain', 'Sponsor:', 'Canopy Growth Corporation', '1 Hersey Drive', 'Smith Falls', 'K7A 0A8', 'Legal Entity', '11318152 Canada Inc.', 'Funding Source:', 'Canopy Growth Corporation', 'Study Sites:', 'Canada', 'Germany', 'United Kingdom', 'Australia', 'Principal Investigator', 'Dr. Dwight Moulin', 'Email: dwight.moulin@gmail.ca', 'Telephone: 519-685-8661', 'Confidentiality Statement', 'This document contains confidential information belonging to Canopy Growth Corporation. The', 'information in this documenti may not be disclosed unless federal or statelawor regulations require', 'such disclosure. Participanto the foregoing, this information may bedisclosed onlyto those persons', 'involved in the study who have a need to know, with the obligation not to further disseminate this', 'information.', '25 November 2020', 'CONFIDENTIAL', 'Page 2 of 79']['CANOPY GROWTH', 'Protocol #710-4502', 'CORPORATION', 'SIGNATURES', 'Sponsor Signature', 'MARK', 'Signed:', 'Date: October 19,2020', 'Dr. Marcel Bonn-Miller', 'VP, Human and Animal Research', 'Canopy Growth Corporation', 'Investigator Signature', 'Signed:', 'Daught moulin', 'Date: October 22, 2020', 'Dr. Dwight Moulin', 'Principal Investigator', '25 November 2020', 'CONFIDENTIAL', 'Page 3 of 79']\n\n###\n\n", "completion": "END"}